Byung-Tae Noh

Directeur Général chez DAE HWA PHARMACEUTICAL CO., LTD.

Fortune : 460 898 $ au 30/04/2024

62 ans

Health Technology

Consumer Services

Profil

Byung-Tae Noh is currently the Chairman & Co-Chief Executive Officer at DAE HWA PHARM Co., Ltd.
He previously worked as a Director at RedoxBio Co., Ltd.
Mr. Noh completed his undergraduate degree at Daegu University.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
RedoxBio Co., Ltd. RedoxBio Co., Ltd. Pharmaceuticals: MajorHealth Technology RedoxBio Co., Ltd. engages in the manufacture and sale of materials for pharmaceutical products. It operates through Hyaluronic Acid and Chemical business divisions. Its products include hyaluronic filler, methylol cephalexin lysinate, sodium hyaluronate, and others. The company was founded on August 26, 2010 and is headquartered in Hwaseong-si, South Korea. 0,41%	31/03/2023	100 000 ( 0,41% )	239 971 $	31/12/2020
DAE HWA PHARM CO., LTD. 0,15%	27/12/2023	27 583 ( 0,15% )	220 927 $	30/04/2024

Postes actifs de Byung-Tae Noh

Sociétés	Poste	Début
DAE HWA PHARMACEUTICAL CO., LTD.	Directeur Général	20/03/2015

Tous les postes actifs de Byung-Tae Noh

Anciens postes connus de Byung-Tae Noh

Sociétés	Poste	Fin
RedoxBio Co., Ltd. RedoxBio Co., Ltd. Pharmaceuticals: MajorHealth Technology RedoxBio Co., Ltd. engages in the manufacture and sale of materials for pharmaceutical products. It operates through Hyaluronic Acid and Chemical business divisions. Its products include hyaluronic filler, methylol cephalexin lysinate, sodium hyaluronate, and others. The company was founded on August 26, 2010 and is headquartered in Hwaseong-si, South Korea.	Directeur/Membre du Conseil	-